SI1587542T1 - Uporaba anti-cd100 protiteles - Google Patents

Uporaba anti-cd100 protiteles

Info

Publication number
SI1587542T1
SI1587542T1 SI200431917T SI200431917T SI1587542T1 SI 1587542 T1 SI1587542 T1 SI 1587542T1 SI 200431917 T SI200431917 T SI 200431917T SI 200431917 T SI200431917 T SI 200431917T SI 1587542 T1 SI1587542 T1 SI 1587542T1
Authority
SI
Slovenia
Prior art keywords
antibodies
Prior art date
Application number
SI200431917T
Other languages
English (en)
Inventor
Marie-Francoise Belin
Pascale Giraudon
Laurence Boumsell
Armand Bensussan
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Publication of SI1587542T1 publication Critical patent/SI1587542T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
SI200431917T 2003-01-31 2004-02-02 Uporaba anti-cd100 protiteles SI1587542T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03290247A EP1442749A1 (en) 2003-01-31 2003-01-31 Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
EP04707230A EP1587542B1 (en) 2003-01-31 2004-02-02 Use of anti-cd100 antibodies
PCT/EP2004/001743 WO2004067034A1 (en) 2003-01-31 2004-02-02 Use of anti-cd100 antibodies

Publications (1)

Publication Number Publication Date
SI1587542T1 true SI1587542T1 (sl) 2012-10-30

Family

ID=32605433

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200431917T SI1587542T1 (sl) 2003-01-31 2004-02-02 Uporaba anti-cd100 protiteles

Country Status (11)

Country Link
US (2) US8067247B2 (sl)
EP (2) EP1442749A1 (sl)
JP (1) JP4768597B2 (sl)
BR (1) BRPI0406689A (sl)
CA (1) CA2514226C (sl)
CY (1) CY1112953T1 (sl)
DK (1) DK1587542T3 (sl)
ES (1) ES2388735T3 (sl)
PT (1) PT1587542E (sl)
SI (1) SI1587542T1 (sl)
WO (1) WO2004067034A1 (sl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576754B2 (en) * 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
EP1442749A1 (en) * 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
WO2008100995A1 (en) * 2007-02-14 2008-08-21 Vaccinex, Inc. Humanized anti-cd100 antibodies
MX2011011718A (es) * 2009-05-08 2012-01-27 Vaccinex Inc Anticuerpos anti-cd100 y metodos para su uso.
EP2487242A1 (en) * 2011-02-09 2012-08-15 Ruprecht-Karls-Universität Heidelberg B-type plexin antagonists and uses thereof
EP2711023B1 (en) 2011-05-13 2017-07-12 National University Corporation Tokyo Medical and Dental University Osteogenesis promoter
EP2766093B1 (en) * 2011-10-11 2018-02-21 Vaccinex, Inc. Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
US9090709B2 (en) * 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) * 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
PL3013350T3 (pl) 2013-06-25 2020-06-15 Vaccinex, Inc. Zastosowanie cząsteczek hamujących semaforynę-4d w kombinacji z terapią modulującą odporność w celu hamowania wzrostu i przerzutów guza
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) * 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
EP3783031B1 (en) 2014-12-03 2023-08-02 Aimed Bio Inc. Antibody against neuropilin 1 and use thereof
IL262232B1 (en) 2016-04-22 2024-02-01 Vaccinex Inc Integral membrane protein display on extracellular enveloped smallpox virions
US11085930B2 (en) 2016-06-03 2021-08-10 Aimed Bio Inc. Anti-NRP1 antibody screening method
RU2747557C2 (ru) 2016-08-02 2021-05-06 Вэксинекс, Инк. Улучшенные способы получения библиотек полинуклеотидов в вирусах осповакцины/эукариотических клетках
MX2019011130A (es) 2017-03-20 2019-11-05 Vaccinex Inc Tratamiento del cancer con un anticuerpo semaforina-4d en combinacion con un agente de modulacion epigenetica.
SG11201909466RA (en) 2017-05-05 2019-11-28 Vaccinex Inc Human anti-semaphorin 4d antibody
EP3824907A4 (en) * 2018-07-19 2022-05-04 The University of Tokyo AGENT FOR THE TREATMENT OR PREVENTION OF HTLV-1 ASSOCIATED MYELOPATHY (HAM), AND METHOD OF TREATMENT OF HAM
EP3946624A1 (en) 2019-03-28 2022-02-09 Vaccinex, Inc. Semaphorin-4d antagonists for use in cancer therapy
US20210032322A1 (en) 2019-08-01 2021-02-04 Vaccinex, Inc. Combined inhibition of semaphorin-4d and tgf-beta and compositions therefor
JP2023532882A (ja) 2020-06-25 2023-08-01 バクシネックス インコーポレーティッド レット症候群の処置のためのセマフォリン４ｄ結合分子の使用
WO2023048726A1 (en) 2021-09-27 2023-03-30 Vaccinex, Inc. Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders
WO2023154906A1 (en) 2022-02-13 2023-08-17 Vaccinex, Inc. Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686087A1 (fr) * 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US5639856A (en) 1993-09-13 1997-06-17 The Regents Of The University Of California Semaphorin gene family
US6576754B2 (en) * 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
US6635742B1 (en) * 2000-01-25 2003-10-21 Nuvelo, Inc. Antibodies specific for semaphorin-like polypeptides
EP1442749A1 (en) * 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system

Also Published As

Publication number Publication date
JP2006516594A (ja) 2006-07-06
ES2388735T3 (es) 2012-10-18
PT1587542E (pt) 2012-07-18
CY1112953T1 (el) 2016-04-13
US8067247B2 (en) 2011-11-29
BRPI0406689A (pt) 2005-12-20
WO2004067034A1 (en) 2004-08-12
US20060233793A1 (en) 2006-10-19
CA2514226C (en) 2015-04-28
EP1587542A1 (en) 2005-10-26
JP4768597B2 (ja) 2011-09-07
DK1587542T3 (da) 2012-07-30
US20120027758A1 (en) 2012-02-02
EP1587542B1 (en) 2012-06-13
EP1442749A1 (en) 2004-08-04
CA2514226A1 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
SI1587542T1 (sl) Uporaba anti-cd100 protiteles
IL175935A0 (en) Solid forms of anti-egfr antibodies
EP1616881A4 (en) ANTI-MPL ANTIBODIES
IL175608A0 (en) Antibodies
PT1599504E (pt) Anticorpo modificado
GB0325192D0 (en) Method of use
EP1494693A4 (en) SPECIFIC ANTIBODIES TO CRIPTO
ZA200604074B (en) Anti-IGFR1 antibody therapeutic combinations
IL173273A0 (en) Modified human igf-1r antibodies
AU158373S (en) Set of containers
PL375405A1 (en) Antibodies
EP1745573A4 (en) PROCESS FOR PREPARING 2-DEOXY-BETA-L-NUCLEOSIDES
EP1699485A4 (en) ANTI-HYDROLYSATE ANTIBODIES AND ITS USES
IL172510A0 (en) Antibodies and uses thereof
IL172511A0 (en) Specific human antibodies
EP1633749A4 (en) DEAZAFLAVIN COMPOUNDS AND METHODS OF USE
HK1155670A1 (en) Therapeutic use of anti-cs1 antibodies
GB0318032D0 (en) Determination of geophone coupling
GB0306618D0 (en) Antibody
PL377902A1 (pl) Nowe zastosowanie kompleksu fosfor-azot-metal
GB2399559B (en) Construction of container
GB0226878D0 (en) Antibodies
HK1209139A1 (en) Modified antibody
GB0329711D0 (en) Antibodies
GB0317974D0 (en) Novel antibodies